Neervannan Seshadri 4

4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 18, 2025

Form 4

Period: 2025-03-15

Chief Operating Officer

Transactions

Exercise/Conversion
Common Stock
2025-03-15+21,264→ 87,265 total
Exercise/Conversion
Restricted Stock Units
2025-03-15−8,019→ 24,060 total
→ Common Stock (8,019 underlying)
Exercise/Conversion
Restricted Stock Units
2025-03-15−5,097→ 5,097 total
→ Common Stock (5,097 underlying)
Exercise/Conversion
Restricted Stock Units
2025-03-15−8,148→ 16,296 total
→ Common Stock (8,148 underlying)

Footnotes (6)

[F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
[F2]Includes 1,234 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2024.
[F3]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
[F4]RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.
[F5]RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
[F6]RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

Documents

1 file